A broad range of unmet needs remains in the immuno-oncology space
Pharmaceutical Technology
MAY 2, 2023
Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. Efficacy-related unmet needs included the need for a greater long-term benefit, higher response rates, and mechanisms for overcoming resistance to IO therapies.
Let's personalize your content